Genome Therapeutics Ltd. has synthesized compounds and their immunoconjugates comprising an antibody covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of ...
Genome Therapeutics Ltd. has disclosed compounds and their immunoconjugates comprising an antibody covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of ...
CD30 expression is not a predictive marker of clinical response to brentuximab vedotin treatment, therefore, development of a biomarker that can identify patients who respond to this agent is ...
BOCA RATON, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (Nasdaq: ENTO) (“Entero” or the “Company”), today announced that it has entered into a binding term sheet for a reverse ...
The ‘809 application relates to dosing for the cancer drug mirvetuximab, an immunoconjugate. Generally, immunoconjugates include (1) an antibody portion typically targeting a cell of interest, and (2) ...
Researchers at the University of California San Diego School of Medicine have identified a promising new therapy for triple-negative breast cancer (TNBC), which is among the most aggressive and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results